{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:58:39Z","timestamp":1787169519303,"version":"build-2736575974"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,2,4]],"date-time":"2003-02-04T00:00:00Z","timestamp":1044316800000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2003,2]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background<\/jats:bold>\n                    : Mesalazine (5\u2010aminosalicylic acid, 5\u2010ASA)\u2010containing formulations represent a cornerstone in the treatment of inflammatory bowel diseases. Recently, a new formulation has been developed to provide selective and more homogeneous release of 5\u2010ASA compared to traditional systems.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods<\/jats:bold>\n                    : In a first study, gastrointestinal transit was followed by gamma\u2010scintigraphy after single\u2010dose application of tablets containing 1200\u2003mg mesalazine to 12 healthy male volunteers. 5\u2010ASA release was verified by the assessment of plasma pharmacokinetics. In a second, 7\u2010day, multiple\u2010dose study, the steady state plasma pharmacokinetics, urinary excretion and safety profile were characterized after twice\u2010daily tablet administration to 12 healthy volunteers.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    : Tablet erosion started after 6.9\u2003\u00b1\u20031.1\u2003h in the ascending or transverse colon. Radioactivity spread homogeneously throughout the colon, indicating the sustained release of active 5\u2010ASA. Plasma kinetics indicated an earlier initial absorption of 5\u2010ASA, i.e. during transit of the small intestine and ileum. Mean\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    values (350.6\u2003\u00b1\u2003322.6\u2003ng\/mL) were observed during location in the ileo\u2010caecal region. The mean relative absorption of 5\u2010ASA was 19.9\u2003\u00b1\u200318.2% in the small intestine and ileum and 80.1\u2003\u00b1\u200318.2% in the colon.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                    : The administration of the new mesalazine formulation was well tolerated, and 5\u2010ASA was continuously released along the whole colon, a favourable prerequisite for the therapy of distally located inflammatory bowel disease.\n                  <\/jats:p>","DOI":"10.1046\/j.1365-2036.2003.01445.x","type":"journal-article","created":{"date-parts":[[2003,3,10]],"date-time":"2003-03-10T22:49:07Z","timestamp":1047336547000},"page":"395-402","source":"Crossref","is-referenced-by-count":62,"title":["Gastrointestinal transit and 5\u2010ASA release from a new mesalazine extended\u2010release formulation"],"prefix":"10.1111","volume":"17","author":[{"given":"M.","family":"Brunner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Assandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kletter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tschurlovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Corrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. G.","family":"Eichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,2,4]]},"reference":[{"key":"e_1_2_21_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb04124.x"},{"key":"e_1_2_21_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280000163"},{"issue":"4","key":"e_1_2_21_4_2","first-page":"479","article-title":"Intestinal metabolism and transport of 5\u2010aminosalicylate","volume":"27","author":"Zhou SY","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_21_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(73)80035-6"},{"key":"e_1_2_21_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1983.tb02254.x"},{"key":"e_1_2_21_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1972134539"},{"key":"e_1_2_21_8_2","unstructured":"Patent WO 00\/76481: Mesalazine Controlled Release Oral Pharmaceutical Compositions 2000."},{"key":"e_1_2_21_9_2","first-page":"69","article-title":"Gastrointestinal behavior of orally administered radiolabelled erythromycin pellets in man as determined by gamma scintigraphy","volume":"5","author":"Digenis GA","year":"1991","journal-title":"J Clin Pharmacol Ther"},{"key":"e_1_2_21_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1993.tb05612.x"},{"key":"e_1_2_21_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00175865"},{"key":"e_1_2_21_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(86)80004-X"},{"key":"e_1_2_21_13_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016475421474"},{"key":"e_1_2_21_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(91)90351-N"},{"key":"e_1_2_21_15_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015806211556"},{"key":"e_1_2_21_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(01)94644-8"},{"key":"e_1_2_21_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)80303-5"},{"key":"e_1_2_21_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200039020-00001"},{"key":"e_1_2_21_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.31.11.1271"},{"key":"e_1_2_21_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006059001800601"},{"key":"e_1_2_21_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00891.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2003.01445.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2003.01445.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T11:33:09Z","timestamp":1697196789000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2003.01445.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["10.1046\/j.1365-2036.2003.01445.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2003.01445.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2]]}}}